48 related articles for article (PubMed ID: 38509620)
21. Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer.
Guo K; Li L
Int J Gen Med; 2021; 14():8237-8248. PubMed ID: 34815697
[TBL] [Abstract][Full Text] [Related]
22. Human Epididymis Protein 4 and Lewis y Enhance Chemotherapeutic Resistance in Epithelial Ovarian Cancer Through the p38 MAPK Pathway.
Gao J; Zhu L; Zhuang H; Lin B
Adv Ther; 2022 Jan; 39(1):360-378. PubMed ID: 34739698
[TBL] [Abstract][Full Text] [Related]
23. Lymphovascular space invasion and estrogen receptor status in high-grade serous ovarian cancer - A multicenter study by the FRANCOGYN group.
Lorenzini J; Deberti M; Body G; Carcopino X; Touboul C; Dabi Y; Collinet P; Coutant C; Akladios C; Lavoué V; Bolze PA; Huchon C; Bricou A; Canlorbe G; Mimoun C; Bendifallah S; Ouldamer L;
J Gynecol Obstet Hum Reprod; 2022 Jan; 51(1):102242. PubMed ID: 34715402
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments.
Marchetti C; De Felice F; Romito A; Iacobelli V; Sassu CM; Corrado G; Ricci C; Scambia G; Fagotti A
Semin Cancer Biol; 2021 Dec; 77():144-166. PubMed ID: 34464704
[TBL] [Abstract][Full Text] [Related]
25. Identification and Functional Validation of Differentially Expressed microRNAs in Ascites-Derived Ovarian Cancer Cells Compared with Primary Tumour Tissue.
Jiang Y; Shi Y; Lyu T; Liu H; Shen L; Zhou T; Feng W
Cancer Manag Res; 2021; 13():6585-6597. PubMed ID: 34456588
[TBL] [Abstract][Full Text] [Related]
26. A machine learning approach to identify predictive molecular markers for cisplatin chemosensitivity following surgical resection in ovarian cancer.
Shannon NB; Tan LLY; Tan QX; Tan JW; Hendrikson J; Ng WH; Ng G; Liu Y; Ong XS; Nadarajah R; Wong JSM; Tan GHC; Soo KC; Teo MCC; Chia CS; Ong CJ
Sci Rep; 2021 Aug; 11(1):16829. PubMed ID: 34413360
[TBL] [Abstract][Full Text] [Related]
27. Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian cancer cells through interactions with Annexin II.
Liu Q; Liu DW; Zheng MJ; Deng L; Wang HM; Jin S; Liu JJ; Hao YY; Zhu LC; Lin B
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33955501
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of CXCL2 is associated with poor prognosis in patients with ovarian cancer.
Zhang F; Jiang J; Xu B; Xu Y; Wu C
Medicine (Baltimore); 2021 Jan; 100(4):e24125. PubMed ID: 33530204
[TBL] [Abstract][Full Text] [Related]
29. Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review).
Yuan J; Lan H; Jiang X; Zeng D; Xiao S
Int J Mol Med; 2020 Oct; 46(4):1255-1265. PubMed ID: 32945348
[TBL] [Abstract][Full Text] [Related]
30. Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation.
Park GY; Pathak HB; Godwin AK; Kwon Y
Cell Oncol (Dordr); 2021 Feb; 44(1):77-92. PubMed ID: 32910411
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer.
Liu J; Jiao X; Gao Q
Drug Discov Today; 2020 Jul; 25(7):1232-1238. PubMed ID: 32360532
[TBL] [Abstract][Full Text] [Related]
32. Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining.
Li H; Li J; Gao W; Zhen C; Feng L
J Ovarian Res; 2020 Mar; 13(1):27. PubMed ID: 32160916
[TBL] [Abstract][Full Text] [Related]
33. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
34. Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
du Bois A; Baert T; Vergote I
J Clin Oncol; 2019 Sep; 37(27):2398-2405. PubMed ID: 31403864
[No Abstract] [Full Text] [Related]
35. Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer.
Lou E; Vogel RI; Hoostal S; Klein M; Linden MA; Teoh D; Geller MA
JAMA Oncol; 2019 Aug; 5(8):1222-1224. PubMed ID: 31152668
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of drug resistance in ovarian cancer - an update.
Davidson B
Expert Rev Mol Diagn; 2019 Jun; 19(6):469-476. PubMed ID: 31075061
[No Abstract] [Full Text] [Related]
37. Biological Insights into Chemotherapy Resistance in Ovarian Cancer.
Glasgow MA; Argenta P; Abrahante JE; Shetty M; Talukdar S; Croonquist PA; Khalifa MA; Starr TK
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31052165
[TBL] [Abstract][Full Text] [Related]
38. Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2.
Yang Y; Li S; Sun Y; Zhang D; Zhao Z; Liu L
Onco Targets Ther; 2019; 12():897-906. PubMed ID: 30774376
[TBL] [Abstract][Full Text] [Related]
39. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms underlying lung resistance-related protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells.
Chen YL; Yang TY; Wu CL; Chen KC; Hsu SL; Hsueh CM
Chin J Physiol; 2016 Dec; 59(6):331-347. PubMed ID: 27817195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
